Sanofi has announced that it will lower the list price of its insulin drug, Lantus, by 78 percent and will set a $35 cap on out-of-pocket costs for all patients.
The price change and cap will go into effect starting January 1, 2024. They follow a series of moves made last year to lower the price of diabetes medicine, including the launch of an unbranded version of Lantus and a $35 cap for uninsured patients.
Yet, Olivier Bogillot, head of U.S. general medicines at Sanofi, said "the health system was unable to take advantage of it due to its inherent structural challenges."
“Sanofi believes that no one should struggle to pay for their insulin and we are proud of our continued actions to improve access and affordability for millions of patients for many years," he said. "Our decision to cut the list price of our lead insulin needs to be coupled with broader change to the overall system to actually drive savings for patients at the pharmacy counter.”
Sanofi will also cut the price of short-acting Apidra by 70 percent.
Learn about Apple's iPhone 15.
Ready4Work focuses on the ins-and-outs of the job market.
Be Well: Best Skincare Products
Be Well: Fall Floral Arrangements
Salary is usually the deciding factor in a job search. Cheddar News' docuseries, "Ready 4 Work," highlights this and much more as it follows six people on their job-hunting journeys and how income is the main goal.
The Federal Trade Commission has begun notifying people that they may be entitled to some claims from Fortnite after a settlement from alleged deceptive business practices.
The Federal Reserve continues to meet over monetary policy but is expected to hold rates steady.
Eli Lilly is suing 10 medical spas, wellness clinics and compounding pharmacies across the country for allegedly selling cheaper counterfeit drugs.
Brenda LaManna, founder and president of Damselfly Flowers, and Warren Schorr, senior vice president with Crayola, joined Cheddar News to discuss how and why the famous Crayon company is launching an online flower business.
Ed Egilinsky, managing director and head of sales and distribution and alternative with Direxion, joined Cheddar News to discuss how short-term traders are preparing for any forward-looking guidance from the Federal Reserve about any potential rate hikes. Egilinsky also discussed how traders are looking at the overall banking sector for the short-term.
